India, March 25 -- image credit- shutterstock

In a move set to redefine non-invasive disease detection, Bengaluru-based Remidio, a global leader in artificial intelligence (AI)-powered ophthalmic solutions, has made a strategic investment in Occuity, a pioneering UK-based developer of handheld, optical screening and monitoring devices that are non-contact and require no consumables.

Remidio and Occuity's partnership will begin with the integration of technologies to co-develop a comprehensive myopia screening solution, addressing India's growing myopia epidemic.

By 2050, nearly 48% of urban children are expected to be affected, with 20% experiencing rapid progression and around 4% facing complications that could lead to permanent visio...